| Time of assessment | ||||
---|---|---|---|---|---|
Screening | Baseline | Post treatment assessment | 6-month Follow-up | 12-month Follow- up | |
Primary outcomes | |||||
 Psychological distress: BSI-53 |  | X | X | X | X |
 Health-related quality of life: EQ-5D-5 L |  | X | X | X | X |
 Medical consumption & costs |  | X | X | X | X |
Secondary outcomes | |||||
 Life satisfaction: Cantril’s Ladder |  | X | X | X | X |
 Mental wellbeing: WEMWBS |  | X | X | X | X |
 Personality functioning: SIPP-SF |  | X | X | X | X |
 Interoceptive body awareness: MAIA |  | X | X | X | X |
 Psychotropic drug use & treatment received |  |  |  |  |  |
 Mood variability: Mood-Zoom |  | X | X | X | X |
Characteristics | |||||
 Personality disorders: SCID-5-PD Cluster B & C | X |  |  |  |  |
 Mental disorders: MINI-Plus | X |  |  |  |  |
 Cognitive screening: MoCA | X |  |  |  |  |
 Psychiatric treatment history: telephone interview |  | X |  |  |  |
 Socio-demographics: telephone interview |  | X |  |  |  |
 Chronic illnesses: LASA questionnaire |  | X |  |  |  |
 Early life-events: NEMESIS questionnaire |  | X |  |  |  |
 Alcohol use: AUDIT |  | X |  |  |  |
 Current smoking: NEMESIS questions |  | X |  |  |  |
 Physical activity: NEMESIS question |  | X |  |  |  |
 Personality traits: PID-5-SF |  | X |  |  |  |